폐암 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global lung cancer therapeutics market size is expected to reach USD 89.63 Billion in 2034 from USD 30.68 Billion in 2025, growing at a CAGR of 12.65 during 2026-2034.This market is experiencing strong growth due to the increasing prevalence of lung cancer and rising demand for advanced treatment solutions worldwide. Growing awareness regarding early diagnosis and improved access to healthcare services are supporting market expansion. Pharmaceutical companies are investing heavily in targeted therapies, immunotherapies, and personalized medicine approaches to improve patient survival rates. Technological advancements in molecular diagnostics and precision oncology are also contributing significantly to the development of innovative therapeutic options.

Rising tobacco consumption, air pollution, and aging populations are major factors driving the demand for lung cancer therapeutics. Healthcare providers are increasingly adopting targeted drugs and immune checkpoint inhibitors because of their effectiveness and reduced side effects compared to traditional chemotherapy. Growing research and development activities in oncology and increasing clinical trials for novel therapies are further strengthening market growth. In addition, supportive government initiatives and cancer awareness programs are positively influencing treatment adoption globally.

Future prospects for the market remain highly promising due to continuous advancements in biotechnology and cancer research. Development of personalized treatment solutions based on genetic profiling is expected to improve therapeutic outcomes significantly. Emerging economies are projected to witness substantial growth because of improving healthcare infrastructure and increasing cancer screening initiatives. As the global burden of lung cancer continues to rise, the market is anticipated to experience sustained long-term expansion across healthcare sectors.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease Type

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)
• Others

By Treatment Modality

• Chemotherapy
• Immunotherapy
• Targeted Therapy

By Drug Class

• Small-Molecule Drugs
• Biologics and Biosimilars

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Line of Therapy

• First-Line
• Second-Line
• Third-Line and Beyond

COMPANIES PROFILED

• F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Merck & Co., Inc., Bristol Myers Squibb Company, Pfizer Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novartis AG, Johnson & Johnson, AbbVie Inc., Amgen Inc., Sanofi, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, BeiGene, Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Non-Small Cell Lung Cancer (NSCLC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Small Cell Lung Cancer (SCLC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY TREATMENT MODALITY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Modality
• 5.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Class
• 6.2. Small-Molecule Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biologics and Biosimilars Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY LINE OF THERAPY 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Line Of Therapy
• 8.2. First-Line Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Second-Line Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Third-Line and Beyond Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Disease Type
  • 9.2.2 By Treatment Modality
  • 9.2.3 By Drug Class
  • 9.2.4 By Distribution Channel
  • 9.2.5 By Line Of Therapy
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Disease Type
  • 9.3.2 By Treatment Modality
  • 9.3.3 By Drug Class
  • 9.3.4 By Distribution Channel
  • 9.3.5 By Line Of Therapy
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Disease Type
  • 9.4.2 By Treatment Modality
  • 9.4.3 By Drug Class
  • 9.4.4 By Distribution Channel
  • 9.4.5 By Line Of Therapy
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Disease Type
  • 9.5.2 By Treatment Modality
  • 9.5.3 By Drug Class
  • 9.5.4 By Distribution Channel
  • 9.5.5 By Line Of Therapy
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Disease Type
  • 9.6.2 By Treatment Modality
  • 9.6.3 By Drug Class
  • 9.6.4 By Distribution Channel
  • 9.6.5 By Line Of Therapy
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL LUNG CANCER THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 F. Hoffmann-La Roche Ltd
  • 11.2.2 AstraZeneca PLC
  • 11.2.3 Merck & Co.Inc
  • 11.2.4 Bristol Myers Squibb Company
  • 11.2.5 Pfizer Inc
  • 11.2.6 Boehringer Ingelheim International GmbH
  • 11.2.7 Eli Lilly And Company
  • 11.2.8 Novartis AG
  • 11.2.9 Johnson & Johnson
  • 11.2.10 AbbVie Inc
  • 11.2.11 Amgen Inc
  • 11.2.12 Sanofi
  • 11.2.13 Takeda Pharmaceutical Company Limited
  • 11.2.14 Daiichi Sankyo Company, Limited
  • 11.2.15 BeiGeneLtd